156 related articles for article (PubMed ID: 18841049)
1. Pathological and molecular heterogeneity of medulloblastoma.
Gulino A; Arcella A; Giangaspero F
Curr Opin Oncol; 2008 Nov; 20(6):668-75. PubMed ID: 18841049
[TBL] [Abstract][Full Text] [Related]
2. Molecular risk stratification of medulloblastoma patients based on immunohistochemical analysis of MYC, LDHB, and CCNB1 expression.
de Haas T; Hasselt N; Troost D; Caron H; Popovic M; Zadravec-Zaletel L; Grajkowska W; Perek M; Osterheld MC; Ellison D; Baas F; Versteeg R; Kool M
Clin Cancer Res; 2008 Jul; 14(13):4154-60. PubMed ID: 18593994
[TBL] [Abstract][Full Text] [Related]
3. Medulloblastoma molecular dissection: the way toward targeted therapy.
Remke M; Ramaswamy V; Taylor MD
Curr Opin Oncol; 2013 Nov; 25(6):674-81. PubMed ID: 24076581
[TBL] [Abstract][Full Text] [Related]
4. Prognostic relevance of clinical and biological risk factors in childhood medulloblastoma: results of patients treated in the prospective multicenter trial HIT'91.
Rutkowski S; von Bueren A; von Hoff K; Hartmann W; Shalaby T; Deinlein F; Warmuth-Metz M; Soerensen N; Emser A; Bode U; Mittler U; Urban C; Benesch M; Kortmann RD; Schlegel PG; Kuehl J; Pietsch T; Grotzer M
Clin Cancer Res; 2007 May; 13(9):2651-7. PubMed ID: 17473196
[TBL] [Abstract][Full Text] [Related]
5. The potential impact of tumour biology on improved clinical practice for medulloblastoma: progress towards biologically driven clinical trials.
Pizer BL; Clifford SC
Br J Neurosurg; 2009 Aug; 23(4):364-75. PubMed ID: 19637007
[TBL] [Abstract][Full Text] [Related]
6. Medulloblastomas in adults: prognostic factors and lessons from paediatrics.
Fellay CN; Frappaz D; Sunyach MP; Franceschi E; Brandes AA; Stupp R
Curr Opin Neurol; 2011 Dec; 24(6):626-32. PubMed ID: 22027544
[TBL] [Abstract][Full Text] [Related]
7. Childhood medulloblastoma: the paradigm shift in molecular stratification and treatment profile.
Sadighi Z; Vats T; Khatua S
J Child Neurol; 2012 Oct; 27(10):1302-7. PubMed ID: 22826514
[TBL] [Abstract][Full Text] [Related]
8. Which clinical and biological tumor markers proved predictive in the prospective multicenter trial HIT'91--implications for investigating childhood medulloblastoma.
Grotzer MA; von Hoff K; von Bueren AO; Shalaby T; Hartmann W; Warmuth-Metz M; Emser A; Kortmann RD; Kuehl J; Pietsch T; Rutkowski S
Klin Padiatr; 2007; 219(6):312-7. PubMed ID: 18050040
[TBL] [Abstract][Full Text] [Related]
9. FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma.
Remke M; Hielscher T; Korshunov A; Northcott PA; Bender S; Kool M; Westermann F; Benner A; Cin H; Ryzhova M; Sturm D; Witt H; Haag D; Toedt G; Wittmann A; Schöttler A; von Bueren AO; von Deimling A; Rutkowski S; Scheurlen W; Kulozik AE; Taylor MD; Lichter P; Pfister SM
J Clin Oncol; 2011 Oct; 29(29):3852-61. PubMed ID: 21911727
[TBL] [Abstract][Full Text] [Related]
10. Medulloblastoma stem cells: where development and cancer cross pathways.
Manoranjan B; Venugopal C; McFarlane N; Doble BW; Dunn SE; Scheinemann K; Singh SK
Pediatr Res; 2012 Apr; 71(4 Pt 2):516-22. PubMed ID: 22430388
[TBL] [Abstract][Full Text] [Related]
11. Recent development in chemotherapy of paediatric brain tumours.
Grill J; Bhangoo R
Curr Opin Oncol; 2007 Nov; 19(6):612-5. PubMed ID: 17906461
[TBL] [Abstract][Full Text] [Related]
12. Childhood medulloblastoma: novel approaches to the classification of a heterogeneous disease.
Ellison DW
Acta Neuropathol; 2010 Sep; 120(3):305-16. PubMed ID: 20652577
[TBL] [Abstract][Full Text] [Related]
13. Histopathological prognostic factors in medulloblastoma: high expression of survivin is related to unfavourable outcome.
Haberler C; Slavc I; Czech T; Gelpi E; Heinzl H; Budka H; Urban C; Scarpatetti M; Ebetsberger-Dachs G; Schindler C; Jones N; Klein-Franke A; Maier H; Jauk B; Kiefer A; Hainfellner JA
Eur J Cancer; 2006 Nov; 42(17):2996-3003. PubMed ID: 16996732
[TBL] [Abstract][Full Text] [Related]
14. Medulloblastoma, WNT-activated/SHH-activated: clinical impact of molecular analysis and histogenetic evaluation.
Cambruzzi E
Childs Nerv Syst; 2018 May; 34(5):809-815. PubMed ID: 29582169
[TBL] [Abstract][Full Text] [Related]
15. [The role of chemotherapy in pediatric medulloblastoma].
Schuler D
Magy Onkol; 2010 Jun; 54(2):145-52. PubMed ID: 20576591
[TBL] [Abstract][Full Text] [Related]
16. Genetics of medulloblastoma: clues for novel therapies.
Onvani S; Etame AB; Smith CA; Rutka JT
Expert Rev Neurother; 2010 May; 10(5):811-23. PubMed ID: 20420498
[TBL] [Abstract][Full Text] [Related]
17. [Childhood medulloblastoma].
Yazigi-Rivard L; Masserot C; Lachenaud J; Diebold-Pressac I; Aprahamian A; Avran D; Doz F
Arch Pediatr; 2008 Dec; 15(12):1794-804. PubMed ID: 18995998
[TBL] [Abstract][Full Text] [Related]
18. OTX1 and OTX2 expression correlates with the clinicopathologic classification of medulloblastomas.
de Haas T; Oussoren E; Grajkowska W; Perek-Polnik M; Popovic M; Zadravec-Zaletel L; Perera M; Corte G; Wirths O; van Sluis P; Pietsch T; Troost D; Baas F; Versteeg R; Kool M
J Neuropathol Exp Neurol; 2006 Feb; 65(2):176-86. PubMed ID: 16462208
[TBL] [Abstract][Full Text] [Related]
19. Gain of 1q is a potential univariate negative prognostic marker for survival in medulloblastoma.
Lo KC; Ma C; Bundy BN; Pomeroy SL; Eberhart CG; Cowell JK
Clin Cancer Res; 2007 Dec; 13(23):7022-8. PubMed ID: 18056178
[TBL] [Abstract][Full Text] [Related]
20. Histologic features and prognosis in pediatric medulloblastoma.
Verma S; Tavaré CJ; Gilles FH
Pediatr Dev Pathol; 2008; 11(5):337-43. PubMed ID: 18201118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
